首页--医药、卫生论文--肿瘤学论文--泌尿生殖器肿瘤论文--女性生殖器肿瘤论文--卵巢肿瘤论文

癌抗原125在卵巢癌早期的表达诊断方法

论文摘要第4-7页
ABSTRACT第7-12页
ChapterⅠ Introduction第18-36页
    1.1 Problematic of the study第20-32页
    1.2 Aims of the present study第32-36页
ChapterⅡ Over Review第36-144页
    2.1 Summary and Definition第36-37页
    2.2 Introduction第37-53页
        2.2.1 Ovarian Cancer Causes第39-41页
        2.2.2 Tumor invasion and metastasis in ovarian cancer第41-42页
        2.2.3 Ovarian Cancer and natural tissue inhibitors第42-45页
        2.2.4 MUC16(mucin 16,cell surface associated)第45-50页
        2.2.5 Ovarian Carcinogenesis by Type Ⅰ and Ⅱ Model第50-53页
    2.3 Diagnosis and staging第53-72页
        2.3.1 Staging of Ovarian Cancer Grouping第53-55页
        2.3.2 Staging in early ovarian cancer stage第55-60页
        2.3.3 Ovarian Cancer Staging System and Recurrent第60页
        2.3.4 FIGO System & TNM System to Stage Ovarian Cancer第60-62页
        2.3.5 Epidemiology studies on CA125 Ovarian cancer diagnosis第62-63页
        2.3.6 Epidemiologic Studies on CA125 and Ovarian Cancer Survival第63-72页
    2.4 Diagnosis & Tests第72-83页
        2.4.1 Exams and Tests第72页
        2.4.2 Ovarian Cancer Symptoms第72-80页
        2.4.3 Early Diagnosis Method第80-83页
    2.5 Women’s female hormones,estrogen and progesterone第83-92页
    2.6 Tumor marker CA125 in ovarian cancer第92-101页
    2.7 Diagnosis of ovarian tumors and types第101-112页
        2.7.1 Current Approach to Type Ⅰ and Type Ⅱ Ovarian Cancer Diagnosis Method第108-110页
        2.7.2 Implications of the ovarian cancer for Early Detection Method第110-112页
    2.8 Imaging Studies第112-119页
    2.9 Clinical studies第119-123页
    2.10 Diagnosis of ovarian tumors and types第123-125页
        2.10.1 Segment clinic第124页
        2.10.2 Fundamental Strand第124-125页
    2.11 Currently suggested Implication of CA125 in early ovarian cancer stage第125-127页
        2.11.1 In Vitro by ELISA studies第125页
        2.11.2 Earl ovarian cancer第125-127页
    2.12 Treatment of ovarian cancer第127-137页
    2.13 The Life Expectancy with Stage Ovarian Cancer第137-139页
    2.14 Recurrent Ovarian Cancer Treatment第139-143页
    2.15 Prognostic factors of ovarian cancer第143-144页
Chapter Ⅲ Material and method第144-152页
    3.1 Specimens and clinical data第144-147页
        3.1.1 Patient population第144-145页
        3.1.2 Control group第145页
        3.1.3 Sample collection第145-147页
        3.1.4 Sizes of tumors at clinical diagnosis第147页
    3.2 The main materials and equipments第147-148页
    3.3 Experimental Study Methods第148-151页
        3.3.1 Samples drawn第148页
        3.3.2 Vitro SPP method第148-150页
        3.3.4 Positive cells criterion(Jacob et al 1989)Positive determination appeared to be significantly higher than the back-round color第150页
        3.3.5 Statistical analysis Methods第150-151页
    3.4 The results第151页
    3.5 The challenges第151-152页
Chapter Ⅳ Results第152-170页
    4.1 ELISA and Samples drawn Evaluation第152页
    4.2 Characterization of CA-125 biomarker samples drawn第152-153页
    4.3 Correlation between CA125 expression and clinicopathological features.Will be show by Pvalue第153-157页
    4.4 Characterization of CA125 expression in ovarian cancer tissues by ELISA study第157-170页
Chapter Ⅴ Discussion第170-200页
Chapter Ⅵ Conclusion第200-204页
References of thesis第204-240页
Reference of Over Review第240-252页
References Literature Cited of CA125 in early ovarian cancer stage第252-258页
Appendix第258-260页
REFERENCES OF PUBLICATION第260-282页
致谢第282页

论文共282页,点击 下载论文
上一篇:基于概念格的动态策略存取模型
下一篇:H移动运营商供应商管理体系优化策略研究